StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
BMO Capital on Vertex (VRTX): 'Ivacaftor Related Label Updates Unlikely to Impact CF Franchise Strength'
March 30, 2026 8:26 AM
BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $600.00 price target on Vertex (NASDAQ: VRTX).The analyst commented ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
